Every 8-K that Nurix Therapeutics, Inc. (NRIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRIX filings page.
Nurix Therapeutics reported fiscal second-quarter 2026 results and unveiled a major global collaboration with Roche for its BTK degrader bexobrutideg.
Revenue was $9.0 million for the quarter ended May 31, 2026, down from $44.1 million a year earlier, mainly because the prior period included $30 million of one-time Sanofi license revenue. Research and development expenses rose to $87.7 million, reflecting higher clinical and manufacturing spend, and net loss widened to $89.5 million, or $0.81 per share.
Nurix ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and cites pro-forma cash of about $1.14 billion, including an expected $700 million upfront payment from Roche. The Roche alliance provides potential total payments of up to $2.3 billion tied to bexobrutideg’s development and commercialization.
Nurix Therapeutics reported updated Phase 1a/1b clinical data for its oral BTK degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug was generally well tolerated across 142 treated patients, including 86 at the 600 mg once-daily recommended Phase 2 dose, with no dose-limiting toxicities and no treatment-related Grade 5 adverse events.
In the Phase 1a cohort of 48 heavily pretreated patients, the objective response rate was 83.0% among 47 evaluable patients, with a median progression-free survival of 22.1 months and responses seen in high-risk subgroups. Earlier-line Phase 1b cohorts showed objective response rates of 92.9% in BTK inhibitor–treated, BCL2 inhibitor–naïve patients and 84.2% in BTK inhibitor–naïve and treatment-naïve patients, with most patients remaining on treatment at the data cutoff.
Nurix Therapeutics entered a global license and collaboration agreement with Roche for bexobrutideg (NX-5948), an investigational oral BTK degrader for cancers and immune diseases. Roche will pay Nurix a $700 million upfront and up to $2.3 billion in potential development, regulatory, and sales milestones.
The partners will co-develop and co-commercialize bexobrutideg in the U.S., sharing development costs 40% Nurix and 60% Roche and splitting U.S. profits and losses 50/50. Outside the U.S., Roche will lead commercialization while Nurix receives tiered royalties from the low teens to the high teens. The deal becomes effective after required antitrust clearances.
Nurix Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held online. A quorum was reached, with 83,747,013 shares of common stock present, representing approximately 80.98% of the voting power entitled to vote as of March 20, 2026.
Stockholders elected three Class III directors—Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva—to three-year terms ending at the 2029 annual meeting. Each will serve until a successor is elected and qualified or earlier resignation or removal.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending November 30, 2026. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
Nurix Therapeutics reported fiscal first quarter 2026 results and updated progress across its clinical pipeline. Revenue was $6.3 million, down from $18.5 million a year earlier as certain Sanofi collaboration research terms ended. Research and development expenses rose to $84.1 million and general and administrative costs increased to $14.6 million, reflecting expanded clinical activity.
Net loss widened to $87.2 million, or ($0.79) per share, compared with ($0.67) per share in the prior-year quarter. Nurix ended the quarter with $540.7 million in cash, cash equivalents and marketable securities. The company highlighted ongoing Phase 2 and planned Phase 3 studies of bexobrutideg in relapsed/refractory chronic lymphocytic leukemia, additional oncology programs, and partnered degraders with Gilead and Sanofi.
Nurix Therapeutics, Inc. updated its existing “at the market” stock offering program by entering into Amendment No. 3 to its equity distribution agreement with Piper Sandler. Under this amendment, the company may, from time to time, offer and sell through Piper Sandler up to $413.65 million of its common stock under its automatic shelf registration statement and related prospectus documents.
Nurix Therapeutics, Inc. filed a current report to note that on January 28, 2026 it issued a press release announcing its financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference.
The company clarifies that the information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.
Nurix Therapeutics, Inc. filed a current report to share that it is presenting at the 44th Annual J.P. Morgan Healthcare Conference. On January 12, 2026, the company is providing an overview of its 2025 performance and outlining major goals for 2026 at the event. The associated investor presentation is included as Exhibit 99.1, and a related press release is included as Exhibit 99.2.
The company notes that this conference information is being furnished under Regulation FD and is not deemed filed for liability purposes under the Securities Exchange Act. The filing is primarily informational and centers on disclosure of the materials used at the conference and the accompanying press release.
Nurix Therapeutics appointed Roger Dansey, M.D. to its Board of Directors and to the Board’s Clinical and Commercialization Committee, effective immediately. He will serve as a Class III director with a term expiring at the company’s 2026 annual meeting of stockholders.
Compensation follows the non-employee director program: a pro rata portion of the $50,000 annual board retainer and a pro rata portion of the $7,500 committee retainer for the remainder of the fiscal year ending November 30, 2025. On November 6, 2025, the Board granted Dr. Dansey an initial stock option for 50,000 shares at the Grant Date closing price, vesting monthly over three years, subject to continued service. He will also be eligible for the customary annual 25,000-share option at each annual meeting, vesting by the next annual meeting or one year, whichever is earlier. Both the Initial Award and each Annual Award accelerate in full upon a Corporate Transaction.
Nurix Therapeutics announced an underwritten public offering, agreeing to issue and sell 24,485,799 shares of common stock at an offering price of $10.21 per share. The company estimates net proceeds of approximately $234.3 million after underwriting discounts, commissions, and expenses.
Nurix plans to use the proceeds primarily to fund clinical development of its drug candidates, including the clinical development of bexobrutideg in chronic lymphocytic leukemia and for potential autoimmune indications, as well as broader R&D, working capital, and general corporate purposes. The offering is being conducted under the company’s shelf registration statement on Form S-3 and a related prospectus supplement, with J.P. Morgan, Jefferies, and Stifel acting as representatives of the underwriters.
Nurix Therapeutics (NRIX) announced initiation of the DAYBreak Phase 2 trial of bexobrutideg (NX-5948), a pivotal single-arm study in relapsed/refractory CLL/SLL. The study will enroll approximately 100 patients whose disease progressed after a covalent BTK inhibitor, a non-covalent BTK inhibitor, and a BCL-2 inhibitor. The primary endpoint is objective response rate per iwCLL criteria assessed by an independent review committee, and the first site was activated in October 2025.
The company selected a 600 mg once-daily dose based on Phase 1b data and alignment with U.S., U.K., and EU regulators, and plans a global randomized Phase 3 confirmatory trial in the first half of 2026 with ~400 patients comparing bexobrutideg to investigator’s choice regimens. Nurix also reported Phase 1a data for NX-1607 in solid tumors, with a disease control rate of 49.3% among 71 evaluable patients as of July 26, 2025, including a confirmed partial response in MSS colorectal cancer and a tolerable safety profile.
Nurix Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal quarter ended August 31, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company states that the information under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal liability purposes.
Nurix Therapeutics, Inc. is planning meetings with securities analysts, investors and others beginning on September 3, 2025 and will use an updated investor presentation in those discussions. The presentation focuses on clinical development plans for bexobrutideg (NX-5948), an investigational oral, brain-penetrant degrader of Bruton's tyrosine kinase that is in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies. The investor presentation is provided as Exhibit 99.1 and is furnished under a Regulation FD disclosure, rather than being treated as filed under the securities laws.
Nurix Therapeutics reported a board committee leadership change following the resignation of Dr. Kunkel. The board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., who is already a board member and a member of the Clinical and Commercialization Committee, to serve as chair of that committee effective September 1, 2025. The change is administrative and focused on committee leadership; no financial data, transactions, or other operational actions are disclosed in the filing.